Cyclarity Therapeutics Receives FDA Investigational New Drug Clearance for UDP-003 to expand Atherosclerosis Clinical Development Program into the United States
Cyclarity Therapeutics announces FDA IND clearance for UDP-003, enabling U.S. expansion of its clinical program, including Phase 1b trials in CAD patients.
Cyclarity Therapeutics announces FDA IND clearance for UDP-003, enabling U.S. expansion of its clinical program, including Phase 1b trials in CAD patients.
Posted: 2026-11-12 19:34:00
CVRx faces allegations it misled investors about misconduct that exposed the Company to liability under the False Claims Act and Anti-Kickback Statute. ...
NEW YORK, Nov. 12, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Alphabet Inc. (NASDAQ: GOOGL, GOOG) between May 19, 2026 and July 16, 2026, inclusive (the “Class Period”), of the important December 1, 2026 lead plaintiff deadline. ...
WILMINGTON, Mass., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Liberty Defense Holdings Ltd. ("Liberty" or the "Company") (NASDAQ: DETX; TSXV: SCAN), a leading provider of AI-based next-generation detection solutions for concealed weapons and threats, today announced that it has engaged Global Impact Advisors LLC ("GIA") to provide investor relations, strategic communications, and capital markets advisory s...
Atlas Air Worldwide and Nippon Cargo Airlines marked the 10th anniversary of their strategic partnership. ...
Related Bing News Results Globe Newswire, World News and Updates | Ottawa Sun Wed, 11 Nov 2026 16:00:00 GMT Globe Newswire Sienna Reports Third Quarter 2026 Financial Results and Continues Platform Growth MARKHAM, Ontario, Nov. 12, 2026 (GLOBE NEWSWIRE) — Sienna Senior Living Inc. (“Sienna” or the “Company” ...
Flying The Web For News.
